MiReven nabs US patent for anticancer technology
01 May, 2014 by Dylan Bushell-EmblingMiReven has picked up its first US patent for the microRNA precursor based anticancer technology developed by the Harry Perkins Institute of Medical Research.
The microRNA perspective
30 April, 2014 by Susan WilliamsonThe persistently high blood glucose levels associated with diabetes can, over time, cause damage to blood vessels that result in so-called diabetes-related complications. Preventing or reducing diabetes-related complications in the kidney is the focus of some of the work currently underway at the Baker IDI.
Cochlea implant delivers gene therapy
29 April, 2014Electrical pulses delivered from a cochlear implant have been used to deliver gene therapy and succesfully regrow auditory nerves.
Prima starts recruiting for ovarian cancer trial
28 April, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has signed up the first patient for CAN-004, its phase II trial of therapy candidate CVac in epithelial ovarian cancer.
CNS to help plan pancreatic cancer trial
22 April, 2014 by Dylan Bushell-EmblingCNS has secured a deal to provide clinical and regulatory services for a Nuvilex pancreatic cancer treatment candidate, including planning for an Australian phase IIb trial.
Funding for prostate cancer research
22 April, 2014Funding is available for translational research in prostate cancer.
The evolution of chloroquine
17 April, 2014A different way of administering chloroquine could see its renewed use to treat malaria.
Innate to start recruiting for SPMS trial in June
16 April, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) expects to start recruiting up to 90 secondary progressive multiple sclerosis patients for a phase IIb trial of MIS416 in June.
BioProspect to acquire mental illness test
14 April, 2014 by Dylan Bushell-EmblingBioProspect (ASX:BPO) will acquire a stake in Invatec and a global licence to a potential heart rate-based diagnostics test for a wide range of mental health disorders.
Burnet research and development agreement with China
14 April, 2014The Burnet Institute has signed a $5 million agreement with China to support the development of low-cost diagnostic tests.
Starpharma secures expanded deal with AstraZeneca
11 April, 2014 by Dylan Bushell-EmblingAstraZeneca has arranged to evaluate using Starpharma's DEP dendrimer drug delivery technology for a second cancer drug.
Minomic plans US trials for prostate cancer test
09 April, 2014 by Dylan Bushell-EmblingMinomic International has tapped CUSP Group to help conduct two US trials of MiSat, a prostate cancer screening tool which has shown signs of being more accurate than the standard PSA test.
Viralytics' Cavatak shows immunotherapy potential
08 April, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) announced that its Cavatak cancer treatment showed signs of oncolytic activity during a phase II trial, and of synergy with a new class of cancer therapy during lab tests.
Regeneus picks US manufacturing partner for Kvax
07 April, 2014 by Dylan Bushell-EmblingRegeneus (ASX:RGS) has selected Hennessy Research to manufacture its canine cancer immunotherapy Kvax for the marketing trials and product launch in the US.
Patrys produces IgM antibodies using plants
03 April, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has published data on a study involving using a plant-based production system to produce IgM antibodies such as the company's anticancer candidate PAT-SM6.
